HOLON, Israel, March 21, 2022 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN), (“Compugen,” the “Company”), a clinical-stage most cancers immunotherapy company and a pioneer in computational goal discovery, right now declared that it will give a presentation nowadays on exploring the immune-tumor microenvironment (TME) utilizing significant resolution one-mobile spatial transcriptomics at the Keystone Symposium: Most cancers Immunotherapy: Decoding the Most cancers Immunity Interactome, March 20-24 at Whistler, British Columbia, Canada.
“Compugen’s predictive computational platform is the cornerstone of our drug discovery and development capabilities. The biology of the TME is complex, and an in-depth comprehending is required to establish novel most cancers immunotherapies,” claimed Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. “At the Keystone Symposium, we will share how we are efficiently using large resolution single mobile spatial mapping of immune cells to decipher this complexity. Leveraging our lengthy-term expertise in computational immuno-oncology biology we have used a chopping-edge technology to deliver an unparalleled look at into the composition and spatial localization of unique cells in the TME. First results further more recommend the existence of the DNAM-1 pathway such as PVRIG, an immune checkpoint uncovered by Compugen, at the web sites of T mobile priming, including the tertiary lymphoid constructions. This is remarkable as it confirms what we have seen previously and further supports the rationale to block PVRIG to tackle immunotherapy resistance in both of those inflamed and much less inflamed tumors. Our potential to review most cancers at the spatially fixed one-mobile amount is expanding our being familiar with of the complicated interactions in the TME and opens the door to new therapeutic strategies.”
Compugen’s cloud-dependent computational system integrates proprietary omics facts, this sort of as proteomics and spatial single-mobile transcriptomics with general public domain genomics and medical metadata in direction of a device learning dependent discovery of novel immuno-oncology distinct targets, biomarkers, and mechanism of motion. The computational-driven hypotheses are then promptly examined and validated by an internal soaked-lab experimental group. The validated data is built-in again into the discovery cycle, furnishing an more layer of proprietary info which is being used to additional improve the computational predictive designs. This restricted in-house integration of computational prediction with experimental validation is just one of Compugen’s strengths and has proved to be vital in its immuno-oncology discoveries, scientific-phase packages, and pipeline development.
Presentation & poster aspects
Assembly title: Most cancers Immunotherapy: Decoding the Cancer Immunity Interactome
Session title: Imaging Cancer Immunity
Presentation & poster title: Checking out the immune-tumor microenvironment working with high resolution single-mobile spatial transcriptomics
Direct creator: Roy Granit
Oral presentation day: Monday, March 21, 2022
Poster day: Tuesday, March 22, 2022
Poster number: Poster #2041
The presentation is available on the publication part of Compugen’s web-site www.cgen.com.
Compugen is a scientific-stage therapeutic discovery and progress business utilizing its broadly applicable predictive computational discovery capabilities to detect new drug targets and organic pathways for creating cancer immunotherapies. Compugen has designed two proprietary solution candidates: COM701, a probable to start with-in-course anti-PVRIG antibody, for the cure of solid tumors, in Phase 1 as a one agent and in dual, and triple mixtures COM902, a possible most effective-in-course monoclonal antibody concentrating on TIGIT for the cure of solid and hematological tumors, undergoing Phase 1 research as a one agent and in twin mixture with COM701. Partnered packages consist of an antibody targeting ILDR2 in Period 1 enhancement, certified to Bayer beneath a analysis and discovery collaboration and license arrangement, and a TIGIT/PD-1 bispecific derived from COM902 (AZD2939) in Section 1/2 enhancement by AstraZeneca via a license settlement for the progress of bispecific and multi-precise antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology applications consists of applications aiming to address a variety of mechanisms of immune resistance, like myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen’s shares are shown on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Ahead-On the lookout Statement
This push release includes “ahead-looking statements” in just the that means of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These kinds of ahead-looking statements are based on the existing beliefs, anticipations, and assumptions of Compugen. Ahead-hunting statements can be discovered making use of terminology this kind of as “will,” “could,” “expects,” “anticipates,” “thinks,” “probable,” “plan,” “objective,” “estimate,” “possible,” “really should,” “self-confident,” and “intends,” and very similar expressions that are supposed to establish ahead-hunting statements, even though not all ahead-wanting statements incorporate these determining words and phrases. Ahead-searching statements include things like, but are not restricted to, statements about our use of chopping-edge technological know-how to provide an unparalleled watch into the composition and spatial localization of unique cells in the TME, that initial findings further more recommend the existence of the DNAM-1 pathway together with PVRIG, an immune checkpoint uncovered by Compugen, is situated at the web-sites of T cell priming, which include the tertiary lymphoid constructions and that it confirms what we have noticed beforehand and further more supports the rationale to block PVRIG to address immunotherapy resistance in both equally inflamed and a lot less inflamed tumors and statement that our capacity to research most cancers at the spatially settled solitary-mobile amount is increasing our knowing of the advanced interactions in the TME and opens the doorway to new therapeutic ways. These forward-on the lookout statements involve recognised and mysterious threats and uncertainties that may possibly lead to the true effects, overall performance, or achievements of Compugen to be materially distinctive from any long run final results, efficiency or achievements expressed or implied by these kinds of forward-hunting statements. Among these hazards: In the in the vicinity of phrase, Compugen is extremely dependent on the good results of COM701 and of COM902 Compugen may perhaps not be capable to progress its interior clinical phase courses as a result of clinical development or production or efficiently partner or commercialize them, or acquire promoting acceptance, possibly by itself or with a collaborator, or may possibly experience substantial delays in executing so Scientific progress includes a prolonged and costly course of action, with an uncertain result and Compugen might come upon significant delays or even an incapacity to commence medical trials for any certain merchandise or may not be capable to conduct or total its trials on the timelines it expects Compugen has minimal experience in the advancement of therapeutic merchandise candidates, and it may be not able to put into action its company method. These risks and other threats are extra entirely discussed in the “Risk Factors” part of Compugen’s most modern Yearly Report on Kind 20-F as filed with the Securities and Exchange Fee (SEC) as well as other documents that may perhaps be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-wanting statements signify Compugen’s views only as of the date of this release and must not be relied on as representing its views as of any subsequent date. Compugen does not suppose any obligation to update any ahead-on the lookout statements except if demanded by regulation.
Firm Speak to:
Yvonne Naughton, Ph.D.
Head of Trader Relations and Corporate Communications
E mail: [email protected]
Tel.: +1 (628) 241-0071
Supply Compugen Ltd.